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Abstract: Blood is an ideal tissue for the identification of novel genomic biomarkers for 
toxicity or efficacy. However, using blood for transcriptomic profiling presents significant 
technical challenges due to the transcriptomic changes induced by ex vivo handling and the 
interference of highly abundant globin mRNA. Most whole blood RNA stabilization and 
isolation methods also require significant volumes of blood, limiting their effective use in 
small animal species, such as rodents. To overcome these challenges, a QIAzol-based RNA 
stabilization and isolation method (QSI) was developed to isolate sufficient amounts of 
high quality total RNA from 25 to 500 μL of rat whole blood. The method was compared 
to the standard PAXgene Blood RNA System using blood collected from rats exposed to 
saline or lipopolysaccharide (LPS). The QSI method yielded an average of 54 ng total 
RNA per μL of rat whole blood with an average RNA Integrity Number (RIN) of 9, a 
performance comparable with the standard PAXgene method. Total RNA samples were 
further processed using the NuGEN Ovation Whole Blood Solution system and cDNA was 
hybridized  to  Affymetrix Rat  Genome  230 2.0 Arrays. The microarray QC parameters 
using RNA isolated with the QSI method were within the acceptable range for microarray 
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analysis. The transcriptomic profiles were highly correlated with those using RNA isolated 
with the PAXgene method and were consistent with expected LPS-induced inflammatory 
responses.  The  present  study  demonstrated  that  the QSI  method coupled  with  NuGEN 
Ovation  Whole  Blood  Solution  system  is  cost-effective  and  particularly  suitable  for 
transcriptomic profiling of minimal volumes of whole blood, typical of those obtained with 
small animal species.  
Keywords: blood; biomarker; inflammation; transcriptomics 
Abbreviations:  QSI:  QIAzol-based  RNA  stabilization  and  isolation  method;  
LPS:  lipopolysaccharide;  RIN:  RNA  Integrity  Number;  PBMC:  peripheral  blood 
mononuclear cells 
 
1. Introduction 
Global  transcriptomic  profiling  is  a  useful  tool  to  identify  novel  biomarkers  for  disease  and  
toxicity [1–4]. To date, most genomic biomarkers have been identified using solid tissues, such as 
liver, kidney, or neoplastic masses. However, it is usually impractical to obtain tissue biopsies in 
clinical studies or for continuous pre-clinical monitoring.  
Peripheral blood has obvious advantages for biomarker discovery due to its non-invasive collection 
and availability. In addition, biomarkers identified in blood should be easily translated from preclinical 
species to humans. A number of studies have demonstrated that transcriptomic changes in peripheral 
blood can serve as biomarkers of exposure to xenobiotics or as biomarkers for pathological changes 
occurring in other tissues [5–8]. 
Peripheral blood mononuclear cells (PMBCs) can be used for genomics biomarker studies since 
they are the most transcriptionally active cells in blood. However, the extra fractionation procedure 
required for PBMCs can have a significant impact on the transcriptome [9]. Isolation of PBMCs at  
the time of blood collection can also be a major limitation in large clinical trials as the procedure 
requires  skilled technicians  and  specialized  equipment. As a  result, whole  blood becomes a more 
attractive sample for blood-based genomic biomarker discovery. However, the use of whole blood for 
transcriptomic profiling presents a number of significant technical challenges.  
First, RNA degradation and transcriptomic changes can occur quickly after the blood is drawn from 
subjects  [10,11].  Traditional  reagents,  such  as  citrate  salts,  heparin,  and  EDTA,  inhibit  blood  
clotting, but do not stabilize mRNA transcripts [12]. Up-regulation of genes related to hypoxia and 
down-regulation of genes related to metabolism and cell cycle have been observed in whole blood 
samples when RNA was not immediately isolated after blood collection [11].  
Attempts to overcome these hurdles led to the development of a number of new approaches for 
blood RNA stabilization [13]. One of those is the PAXgene blood RNA system that has been widely 
used in clinical settings for blood transcriptomic studies. The PAXgene system uses a proprietary 
reagent that stabilizes RNA immediately upon blood collection, making it possible to store samples for 
relatively long periods of time without compromising RNA integrity [12,14]. Although this system Int. J. Mol. Sci. 2011, 12                   
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allows for easy blood collection, storage, and transport, its use in pre-clinical settings is significantly 
limited by its volume requirement. The PAXgene Blood RNA System is designed for the isolation of 
total RNA from 2.5 mL human whole blood. In animal models, particularly in rodents, such volumes 
are not usually achievable even at terminal blood draws especially when other parameters, such as 
clinical chemistry, need to be evaluated in parallel.  
The second major concern for whole blood transcriptomic analysis is the interference from globin 
mRNA. Whole blood contains abundant α- and β-globin mRNA transcripts that comprise up to 70%  
of  total  mRNA  [15].  Such  a  high  abundance  of  globin  mRNA  can  significantly  mask  the  signal  
of  low  abundance  transcripts  as  a  result  of  non-specific  cross-hybridization  with  non-globin  
transcripts [16,17]. Technologies to reduce globin mRNA, such as GLOBINclear (Ambion, Applied 
Biosystems) or globin peptide nucleic acid (PNA) oligos, are time-consuming, low throughput, and 
prone  to  additional  experimental  variability  [17].  Although  the  globin  reduction  procedures  can 
efficiently  increase  the  overall  sensitivity  of  transcript  detection,  they  may  also  reduce  the  signal 
intensities for other transcripts [16,18,19]. 
In order to overcome these challenges, we have developed a simple whole blood processing method 
that immediately stabilizes RNA upon blood collection and yields high quality RNA from as little as 
25 µ L of rat whole blood. To circumvent the need for a separate globin reduction procedure, the 
NuGEN  Ovation  Whole  Blood  Solution  was  employed  for  microarray  sample  preparation.  The 
NuGEN approach hybridizes biotinylated cDNA onto the microarray and has been shown to have 
sufficient sensitivity and reproducibility with small amounts of input RNA [17]. Using blood from rats 
exposed to lipopolysaccharide (LPS) as a model system, the present study demonstrates that the RNA 
isolated  by  the  proposed  QIAzol-based  stabilization  and  isolation  method  (QSI)  can  provide  
robust  transcriptomic  profiles  comparable  to  those  obtained  from  RNA  isolated  with  the  standard 
PAXgene system. 
2. Results and Discussion  
2.1. Results 
2.1.1. Quantity and Quality Assessment of Total RNA Isolated from Rat Whole Blood Using the 
PAXgene and QSI Methods 
Total RNA was isolated from 2.5 mL rat whole blood using the standard PAXgene method or from 
500 μL rat whole blood using the QSI method. When normalized with blood volume, the total RNA 
yield from the PAXgene method was approximately twice the yield from the QSI method (Table 1).  
Given the small amount of input RNA required for NuGEN Whole Blood Solution, both isolation 
methods yielded a sufficient amount of RNA for microarray analysis. RNA quality from both isolation 
methods was excellent with an average RIN score of 9.  
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Table  1.  Quantity  and  quality  of  total  RNA  isolated  from  rat  whole  blood  using  the 
PAXgene or QSI method. 
Method 
RNA Yield (ng/L 
whole blood) 
RIN Score 
PAXgene  44.9 ±  5.6  9.0 ±  0.2 
QSI_500   21.0 ±  1.3  8.8 ±  0.4 
QSI_200  33.6 ±  5.4  9.5 ±  0.2 
QSI_100  79.4 ±  7.0  8.5 ±  0.5 
QSI_50  69.0 ±  6.3  8.8 ±  0.2 
QSI_25  65.4 ±  6.0  8.8 ±  0.2 
Samples were extracted from rats treated with saline or LPS for 2 hrs. Values are expressed as mean ±  SEM (n = 6). 
2.1.2. RNA Isolated from the PAXgene and QSI Methods Yield Comparable Affymetrix GeneChip® 
Array Performance  
The array performance metrics are summarized in Table 2. The percent present calls (% P) for the 
RNA  samples  isolated  using  the  QSI  method  were  generally  lower  than  those  produced  from  
the PAXgene method (p-value < 0.05). However, there was no significant difference in the GAPDH 
3'/5' ratios and β-actin 3'/5' ratios between the PAXgene and the QSI methods. 
Table 2. GeneChip array performance matrices. 
Method  % Present  GAPDH 3'/5' Ratio  Actin 3'/5'/Ratio 
PAXgene  47.5 ±  2.1  2.7 ±  0.03  8.9 ±  0.3 
QSI_500  37.9 ±  3.6*  2.5 ±  0.11  8.9 ±  1.2 
QSI_200  37.2 ±  2.3*  2.7 ±  0.08  8.4 ±  0.3 
QSI_100  33.7 ±  5.1*  2.9 ±  0.15  10.1 ±  1.1 
QSI_50  37.0 ±  3.1*  2.8 ±  0.12  9.8 ±  1.1 
QSI_25  36.5 ±  4.4*  2.7 ±  0.14  8.5 ±  0.6 
Samples were extracted from rats treated with saline or LPS for 2 hrs. Values are expressed as mean ±  SEM 
(n = 6). * Significant difference from the PAXgene method (p < 0.05). 
2.1.3. The PAXgene and QSI Methods Yield Comparable Blood Transcriptomic Profiles in Rats 
Exposed to LPS 
LPS induced the highest number of gene expression changes in rat blood at 2 hrs, followed by 6 hrs 
and 24 hrs. Figure 1 showed the agglomerative hierarchical clustering of gene expression profiles from 
blood samples of LPS-treated rats. The gene expression profiles were clustered according to treatment 
time,  but  not  to  the  RNA  isolation  method.  Furthermore,  the  variability  introduced  by  the  RNA 
isolation methods was no greater than the underlying biological variability among rats. For instance, 
the pair-wise correlation coefficients between the transcriptomic changes from any two rats treated 
with LPS for 2 hrs was 0.84 ±  0.02 using RNA isolated with the PAXgene method, and 0.87 ±  0.01 
using RNA isolated with the QSI method. This was comparable to the pair-wise correlation coefficient 
between  the  transcriptomic  changes  using  input  RNA  isolated  by  either  methods  from  the  same 
animal, which was 0.86 ±  0.01 (p-value = 0.44 and 0.43, respectively). Int. J. Mol. Sci. 2011, 12                   
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Figure 1. Agglomerative hierarchical clustering of gene expression profiles from blood 
samples  of  LPS-treated  rats.  Gene  expression  data  were  calculated  by  normalizing 
treatment to time-matched vehicles using the same RNA isolation method. Each column 
represents a single Affymetrix probe set and each row an experimental treatment. Only 
transcripts with a fold change higher than 2 fold and a p-value less than 0.01 in at least one 
ratio experiments are displayed (n = 6197). Increases in mRNA level are represented as 
shades  of  red  and  decreases  as  shades  of  green.  If  the  p-value  for  a  particular  gene 
expression change was greater than 0.01, the log10(ratio) was represented as zero or black 
on the heat map. * denotes gene expression profiles from blood RNA samples isolated with 
the QSI method. 
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To address whether blood RNA isolation methods could selec tively affect transcripts of different 
abundance, the gene expression levels of a panel of  nine transcripts representing various abundance 
levels were  further  evaluated  using  the  2 -hr  time  point  samples.  The  signal  intensities  of  the  low 
abundance transcripts were less than 3-fold of the microarray background signals. The intensity of the 
mid abundance transcripts were 14–26-fold above background levels, while the intensities of the high 
abundance transcripts were over 80-fold above background, representing the top 5th percentile of the 
rat genome. Each abundance category contained a transcript that was up-regulated, down-regulated, or 
unchanged (less than 2-fold relative to control treatments) by LPS treatment. The list of transcripts is 
provided  in  the  supplemental  table.  As  shown  in  Figure  2,  the  magnitudes  of  changes  in  gene 
expression from samples isolated with the QSI method were almost identical to the ones from the 
PAXgene isolation method. The r
2 was over 0.9 in any abundance category.  
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Figure  2.  Effects  of  blood  RNA  isolation  methods  on  gene  transcripts  of  different 
abundance. The gene expression changes are compared between samples isolated with the 
PAXgene and QSI methods for selective gene transcripts with low, mid, and high basal 
gene expression levels. Data on both axes are expressed as the log10 gene expression ratios 
from the individual LPS-treated sample vs. the vehicle controls at the 2-hr time point. 
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To evaluate the impact of the RNA isolation method on characterization of biological functions, 
blood  transcriptomic  profiles  were  also  subjected  to  pathway  analysis  using  Ingenuity  Pathway 
Analysis Software. The analysis was focused on the samples from the 2-hr time point since they 
represented  the  peak  transcriptomic  changes  induced  by  LPS.  As  expected,  LPS  induced  gene 
expression  changes  consistent  with  perturbation  of  immune  responses.  Regardless  of  the  RNA 
isolation  method,  the  top  five  regulated  physiological  functions  were:  hematological  system 
development  and  function,  immune  cell  trafficking,  cell-mediated  immune  response,  and  tissue 
morphology. In addition, the top five most impacted canonical signaling pathways were the same with 
the two RNA isolation methods (Table 3). Figure 3 shows a comparison of the gene expression data 
between the two isolation methods for the genes in the top two canonical pathways, namely interferon 
and IL-10 pathways. In both cases, the gene expression changes showed almost a 1:1 relationship with 
an r
2 > 0.9.  
Table 3. Top five canonical signaling pathways regulated in rat blood by LPS treatment for 2 hrs. 
Pathway  RNA Isolation Methods 
Total # of Genes in 
Pathway 
# of Regulated 
Genes in Pathway* 
% 
Regulated  
Interferon Signaling 
PAXgene 
30 
13  43 
QSI_500  12  40 
QSI_25  13  43 
IL-10 Signaling  PAXgene 
70 
23  33 
  QSI_500  26  37 
  QSI_25  23  33 
Activation of IRF by 
Cytosolic Pattern 
Recognition Receptors 
PAXgene  74  23  31 
 
QSI_500 
 
22  30 
QSI_25  25  34 Int. J. Mol. Sci. 2011, 12                   
 
 
2508 
Table 3. Cont. 
Death Receptor 
Signaling 
PAXgene 
64 
19  30 
QSI_500  18  28 
QSI_25  20  31 
Role of PKR in 
interferon Induction and 
Antiviral Response 
PAXgene 
46 
13  28 
QSI_500  14  30 
QSI_25  16  35 
Genes were considered regulated if the average fold changes were greater than 2 fold over vehicle controls 
with p-value < 0.01.  
Figure 3. Effects of blood RNA isolation methods on genes in the interferon and IL-10 
pathways. The gene expression changes are compared between samples isolated with the 
PAXgene and QSI methods for the genes in the interferon (A) and IL-10 (B) pathways. 
Data on both axes are expressed as the average log10 gene expression ratios from the LPS 
treated samples vs. the vehicle controls. Only genes with a fold change higher than 2 fold 
and p-value < 0.01 in either isolation methods are included in the analysis. 
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2.1.4. Quantitative RT-PCR Validation of Microarray Results 
To  confirm  the  microarray  results,  the  expression  levels  of  the  same  panel  of  9  transcripts 
representing different abundance levels were measured by real -time RT-PCR using 2-hr blood RNA 
samples  isolated with  the PAXgene  method.  Consistent  with  the  microarray  results,  the  transcripts 
were shown to be regulated in the same direction for all abundance levels (Table 4). The transcripts 
unchanged per microarray measurement were also shown to not be regulated by RT-PCR, except for Int. J. Mol. Sci. 2011, 12                   
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the low abundance transcripts which fluctuated further away from vehicle control when measured by 
RT-PCR.  However,  given  the  low  basal  expression  level,  these  changes  are  not  likely  to  be 
biologically  significant.  These  results  indicated  that  the  NuGEN  Whole  Blood  Solution,  while 
reducing the interference associated with highly abundant globin mRNA transcripts, did not selectively 
amplify genes according to their abundance.  
Table  4.  Quantitative  RT-PCT  validation  of  microarray  results  on  selected  
gene transcripts. 
Gene Symbol 
Abundance 
Level 
Regulated by 
LPS according 
to Microarray 
Fold Change over Vehicle 
Microarray  RT-PCR 
Tcf7  High  Down  −4.25 ± 0.75  −7.74 ± 1.59 
Nrp1  Mid  Down  −19.22 ± 4.13  −4.65 ± 0.27 
Map2k6  Low  Down  −5.16 ± 0.64  −16.92 ± 4.63 
Alas2  High  No Change  0.37 ±  0.69  0.55 ±  0.63 
Canx  Mid  No Change  −1.22 ± 0.02  −1.10 ± 0.04 
Flad1  Low  No Change  −1.23 ± 0.04  −2.77 ± 0.31 
S100a9  High  Up  5.52 ±  0.62  16.70 ±  3.80 
Il1b  Mid  Up  5.35 ±  0.99  9.19 ±  1.61 
Tnf  Low  Up  6.04 ±  1.23  3.94 ±  0.76 
Values are expressed as mean ±  SEM from three animals treated with 5 mg/kg of LPS for 2 hrs. Blood RNA 
was isolated with the PAXgene method. 
2.1.5. Evaluation of the QSI Method Using Small Volume of Whole Blood as Input  
To assess if small blood volumes are adequate for transcriptomic profiling using the QSI method, 
various volumes of whole blood (25–200 μL) were collected from rats treated with saline or LPS for  
2 hrs. Transcriptomic profiles were generated using the QSI method for RNA isolation followed by  
the NuGEN method for RNA amplification and target labeling. When normalized with blood volume, 
the  smaller  amount  of  blood  input  yielded  the  greatest  amount  of  total  RNA  produced  by  
volume (Table 1). Furthermore, the QSI method using  100 μL blood yielded over 50% higher total 
RNA per μL of blood than the standard PAXgene method. The quality of RNA isolated from small 
volumes  of  blood,  as  represented  by  RIN  score,  was  similar  to  that  isolated  from  500  μL  whole  
blood (Table 1).  
There were no significant differences in microarray performance using RNA isolated from various 
volumes  of  blood  (Table  2).  Figure  4  shows  the  whole  blood  transcriptomic  profiles  from  the  
LPS-treated rats using RNA isolated from different volumes of whole blood. 
In general, the gene expression profiles were clustered by individual animal, not by blood volume. 
The  impact  of  blood  volume  on  specific  transcript  panels  and  biological  functions  were  further 
evaluated using samples isolated from 500 μL or 25 μL whole blood. The gene expression levels  
from the panel of 9 transcripts representing different abundance levels were highly correlated with an 
r
2 > 0.9 between the two sets of samples (Figure 5). The same top five canonical signaling pathways 
were impacted to a similar extent regardless of the starting blood volume (Table 3).  Int. J. Mol. Sci. 2011, 12                   
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Figure 4. Effects of the starting blood volume on global transcriptomic profiles using the 
QSI method. Gene expression profiles from blood samples of rats exposed to LPS for 2 hrs 
were clustered using the agglomerative hierarchical algorithm. RNA was isolated using 
different  volumes  of  whole  blood  with  the  QSI  method.  Gene  expression  data  were 
calculated by normalizing treatment to the vehicles using RNA isolated from the same 
volume of whole blood. Each column represents a single Affymetrix probe set and each 
row an experimental treatment. Only genes with a fold change higher than 2 fold and  
p-value < 0.01 in at least one experiment are displayed (n = 4406). Increases in mRNA 
level are represented as shades of red and decreases as shades of green. If the p-value for a 
particular gene expression change was greater than 0.01, the log10 (ratio) was represented 
as  zero  or  black  on  the  heat  map.  Note  the  marked  similarity  in  expression  profiles 
indicating that the starting blood volume did not significantly influence microarray data. 
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Figure 5. Effects of the starting blood volume on gene transcripts of different abundance. 
The gene expression changes were compared between samples prepared from 500 uL and 
25  uL  whole  blood  for  selective  gene  transcripts  with  low,  mid,  and  high  basal  gene 
expression levels. Data on both axes are expressed as the log10 gene expression ratios from 
the individual LPS treated sample vs. the vehicle controls at the 2-hr time point. 
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2.2. Discussion 
Identification  of  blood  genomic  biomarkers  of  efficacy  or  toxicity  in  small  preclinical species, 
especially rodents, offers great potential for translation to the clinic. However, the sample collection, 
RNA isolation procedures, and microarray processing methods need to be optimized to small amount 
of whole blood in order to make such research activity practical in animal models. The present study 
describes  a  practical  and  efficient  workflow  using  a  QSI  isolation  method  coupled  with  NuGEN 
Ovation Whole Blood Solution for blood transcriptomic profiling from as little as 25 μL whole blood, 
a volume easily obtained from a standard tail vein bleeding procedure. A comparison with the standard 
PAXgene system demonstrated that the QSI method can produce similar yields of total RNA per 
volume of rat whole blood. The total RNA samples produced from the QSI and the standard PAXgene 
methods  have  an  average  RIN  score  of  9,  well  above  the  RNA  quality  generally  preferred  for 
microarray-based profiling (RIN > 8) [10,20,21]. 
It is possible to modify the standard PAXgene method to isolate RNA from small amounts of whole 
blood. The method by Krawiec et al. [21] yielded an average of 40 ng total RNA per μL whole blood 
with a RIN score of 7.7 from 50 μL mouse whole blood. The method by Robison et al. [22] yielded an 
average of 3.6 ng total RNA per μL whole blood with a RIN score of 9.3 from 70 μL whole human 
blood  collected  via  fingerstick.  The  low  yield  from  this  later  study  is  likely  a  reflection  of  the 
difference between human and rodent blood. In general, the RNA yield and quality were comparable 
to the QSI method reported here. However, both modified PAXgene methods are manual and require 
extra steps to achieve sufficient yield. In contrast, the QSI method can be fully automated. Using the 
Qiagen Automated BioRobot 3000 RNeasy-96 RNA isolation protocol, only 90 min of hands-on time 
is needed to isolate RNA from 96 whole blood samples. The QSI method is also cheaper than the 
PAXgene method. The total cost for 96 samples using the automated QSI method is a quarter of the 
cost of the standard PAXgene method and half the cost of the modified PAXgene method.  
Commercial  RNA  isolation  and  stabilization  kits  that  are  designed  specifically  for  laboratory 
animals  have  also  been  recently  developed  from  several  resources.  The  ZR  Whole  Blood  Total  
RNA  Kit  (Zymo  Research,  Orange,  CA,  USA),  the  Mouse  RiboPure  Blood  RNA  Isolation  
Kit  (Ambion/Applied  Biosystems,  Austin,  TX,  USA),  and  the  RNeasy  Protect  Animal  Blood  
System (Qiagen, Valencia, CA, USA) are designed for blood volumes of 100–500 μL. Whether these 
kits can be further scaled down to 25 μL whole blood remains to be determined.  
Of note, neither the PAXgene system, nor the QSI method removes globin mRNA during the RNA 
isolation process. To reduce the artifacts associated with highly abundant globin mRNA transcripts, 
the  NuGEN  Ovation  Whole  Blood  Solution  procedure  was  used  downstream  of  the  total  RNA 
isolation  from  rat  whole  blood.  Results  with  human  blood  samples  suggested  that  globin  RNA 
amplification can be reduced with the NuGEN procedure [17]. However, in our experience with rat 
whole blood, there was no significant reduction of globin peak in cDNA samples when compared to 
cRNA samples prepared with the standard Affymetrix protocol. Similar results were also noted by the 
manufacturer (personal communication). Rat blood has twice the amount of reticulocytes compared to 
human blood [23]. The difference in globin reduction performance between human vs. rat blood is 
likely a reflection of the high proportion of reticulocytes in rat blood. The NuGEN procedure generates 
cDNA  targets  as  compared  to  the  cRNA  targets  prepared  with  the  standard  Affymetrix  protocol. Int. J. Mol. Sci. 2011, 12                   
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Despite the pronounced globin peak in cDNA targets from rat blood, the procedure is less prone to 
non-specific cross-hybridization with globin transcripts as a result of higher fidelity of DNA-DNA 
hybridization compared to RNA-DNA hybridization [24]. In addition to the reduced interference with 
globin mRNA, the NuGEN procedure requires a relatively small amount (20–50 ng) of total RNA for 
transcriptomic profiling. The QSI method described here can easily yield over 1000 ng total RNA from 
25 uL blood, an amount sufficient for several microarray experiments using the NuGEN procedure.  
A comparison of RT-PCR and microarray results showed good concordance of gene expression 
changes for a panel of 9 transcripts selected to represent low, mid, and high abundance genes. There 
are differences in the absolute fold change measured by RT-PCR and microarray. However, the trend 
(ie., up- or down-regulation) was the same across all abundance levels. The concordance in trend, but 
not in absolute value, is a typical observation between RT-PCR and any type of microarray platform 
regardless of sample resources [25,26]. Although this is only a small sample size relative to the whole 
genome, these results, taken together with the prototypical LPS-induced pathway changes in the blood 
transcriptome,  suggested  that  the  NuGEN  procedure  can  provide  an  accurate  representation  of 
transcripts across different abundance levels.  
The microarray performance metrics showed that the array quality using RNA prepared from the 
PAXgene method was slightly superior to that from RNA isolated with the QSI method. However, the 
QC parameters for all samples were within the acceptable range recommended by the manufacturer 
and the general microarray community [27–30].  
We used LPS-induced acute immune response in rats as a model system to address if the slight 
difference in QC parameters between the two methods affected the representation of gene transcripts 
and biological interpretation. LPS is a component of the bacterial cell wall of Gram negative bacteria 
and activates a complex of pattern recognition proteins in a variety of mammalian cell types, especially 
macrophages [31]. The interaction with the protein complex results in activation of  a downstream 
signaling cascade that eventually leads to the production of pro-inflammatory cytokines, as well as the 
recruitment  of  inflammatory  cells.  In  human  whole  blood,  LPS  induces  transcriptomic  changes 
characterized by increased expression of genes associated with the defense response to pathogens, 
such as cytokines, chemokines, and acute-phase transcription factors, and decreased expression of  
genes associated with lymphocytes and ribosomal proteins [32]. In the present study, the rat blood 
transcriptomic  profiles  revealed  a  pattern  consistent  with  the  underlying  LPS-induced  acute  
immune response, regardless of whether the blood total RNA was isolated with the PAXgene or the 
QSI method. 
3. Experimental Section  
3.1. Animals, Treatment, and Sample Collection 
Male Sprague-Dawley rats [Crl:CD
®(SD)IGS BR] weighing approximately 250 g were obtained 
from Charles River Laboratories, Inc, Portage, MI, USA. The animals were permitted non-certified 
Rodent Chow and water ad libitum. Rats were housed two or three per cage for two days after receipt 
to aid in acclimation.  
Thereafter,  rats  were  single  housed  in  ventilated,  stainless  steel,  wire  bottom  hanging  cages 
equipped with feeders and an automatic watering system. The animals were administered a single Int. J. Mol. Sci. 2011, 12                   
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intravenous injection of vehicle (saline) or LPS (5 mg/kg, Sigma-Aldrich # L2880) and euthanized 2, 
6, or 24 hrs post dosing (3 rats/time point/group). Blood samples were collected via the abdominal 
vaudal vena cava at necropsy for RNA isolation (Figure 6). For the PAXgene method, 2.5 mL of blood 
were collected into PAXgene Blood RNA Tubes according to the manufacturer’s instructions (BD 
Biosciences, San Jose, CA). After incubation for 2 hrs at room temperature, the PAXgene tubes were 
stored at −20 °C  until analysis. For the QSI method, approximately 25 µ L, 50 µ L, 100 µ L, 200 µ L, and 
500 µ L of blood were added to 1 mL or 2 mL (for 500 µ L blood volume only) of QIAzol (QIAGEN, 
Valencia, CA). Upon addition of the blood, the tubes were inverted twice and incubated at room 
temperature for up to 3 hrs before storage at −80° C for future analysis. Experiments were conducted in 
accordance with the Guiding Principles in the Use of Animals in Toxicology [33] and approved by the 
local Institutional Animal Care and Use Committee.  
Figure 6. Flow diagram of the study design. Varying volumes of rat whole blood (25–500 µ L) 
were collected and immediately lysed in QIAzol (25–200 µ L of blood in 1 mL QIAzol,  
500 µ L in 2 mL QIAzol) from rats (n = 3 per time point per treatment) treated with either 
saline  or  LPS.  Blood  (2.5  mL)  was  also  collected  from  each  rat  into  PAXgene  tubes. 
Automated RNA isolation for blood collected directly into QIAzol was performed using 
the Qiagen 3000 BioRobot RNeasy 96 protocol. RNA isolation for PAXgene tubes was 
performed manually according to manufacturer’s instructions. 
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3.2. RNA Isolation  
RNA isolation from samples collected in PAXgene Blood RNA Tubes was performed according  
to the manufacturer’s specifications (BD Biosciences). For the QSI method, total RNA was isolated 
from 750 µ L of blood-QIAzol lysate following the Qiagen Automated BioRobot 3000 RNeasy-96 
RNA  isolation  protocol  (QIAGEN).  After  manual  centrifugation  of  a  96-well  plate  containing  
QIAzol  lysate/chloroform  mixture,  the  Qiagen  BioRobot  3000  automatically  transfers  the  upper, 
aqueous phase to a 96-well RNeasy plate for automated RNA purification. Nucleic acid concentration 
was determined by O.D. 260 nm (NanoDrop ND-1000, Thermo Scientific, Wilmington, DE, USA). 
The  RNA  integrity  was  evaluated  and  an  RNA  Integrity  Number  (RIN)  was  generated  using  an Int. J. Mol. Sci. 2011, 12                   
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Agilent  2100  Bioanalyzer  and  its  accompanying  software  (Agilent  Technologies,  Foster  City,  
CA, USA).  
3.3. Microarray Analysis  
All  blood  RNA samples  were  processed  to  generate  microarray  hybridization  targets  using the 
Ovation Whole Blood Solution (NuGEN Technologies, San Carlos, CA, USA), a module containing 
three NuGEN products. Briefly, 50 ng of DNAase-treated RNA aliquots were amplified using the 
Ovation  RNA  Amplification  System  V2  coupled  with  the  Ovation  WB  Reagent  following  the 
manufacturer’s instructions (NuGEN). Approximately 4.4 g of each amplified single strand cDNA 
sample was then biotinylated and fragmented using the FL-Ovation cDNA Biotin Module V2. The 
resulting cDNA was hybridized to an Affymetrix Rat Genome 230 2.0 Array (Affymetrix, Santa Clara, 
CA, USA) using the NuGEN-modified hybridization protocol, with 2 min of heat denaturation of the 
hybridization cocktail at 99 ° C and a minimum of 16 hrs of hybridization at 45 ° C using an Affymetrix 
Hybridization Oven 640. The array was subsequently washed and stained with streptavidin-phycoerythrin 
(Molecular  Probes)  on  the  Affymetrix  Gene-Chip  Fluidics  Workstation  400  following  the  
NuGEN-recommended protocol EukGE-WS2v4_450. The array was then scanned using an Affymetrix 
GeneChip Scanner 3000.  
3.4. Real-Time Quantitative RT-PCR 
The following primers and probes were selected from the Applied Biosystems Assays-on-Demand gene 
expression products: Tcf7 (Rn_00493446_m1), Map2k6 (Rn_00586764_m1), Nrp1 (Rn_00595457_m1), 
Alas2  (Rn_00566201_m1),  Flad1  (Rn_01512487_m1),  Canx  (Rn_00596877_m1),  S100a9 
(Rn0585879_m1),  Tnf  (Rn_99999017_m1),  Il1b  (Rn_01514151_m1),  and  18S  (Hs_99999901_s1). 
Expression  levels  of  each  gene  were  quantified  by  real-time  RT-PCR  with  an  ABI  Prism  7900 
Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). Briefly, 200 ng of total RNA 
was  reverse  transcribed  using  the  iScript
TM  cDNA  Synthesis  Kit  according  to  the  manufacturer’s 
instructions (Bio-Rad Laboratories). Real-time PCR analyses were then performed in a total volume of 
10 L containing 1:15-diluted synthesized cDNA using Taqman
® Gene Expression Assays (Applied 
Biosystems). The PCR cycling profile was as follows: 10 min at 95 C, followed by 40 cycles of 95 C 
for 15 s and 60 C for 1 min. The relative fold changes were calculated using the delta delta Ct method 
and normalized to 18S ribosomal RNA, the endogenous control gene. 
3.5. Statistical Analysis 
All non-microarray statistical analyses were conducted using JMP 7.0.1 statistical software from 
SAS (Cary, North Carolina). Comparisons were made using the two-tailed t-test with a significance 
value of α = 0.05. For microarray analysis, the scanned image and intensity files were imported into 
Rosetta Resolver gene expression analysis software version 7.2 (Rosetta Inpharmatics, Seattle, WA). 
Individual gene expression ratios were built for each treatment animal versus the averaged vehicle 
controls  at  the  corresponding  conditions  using  the  Rosetta  Resolver  error  model  [34].  Genes  and 
experimental treatments were grouped for visualization by agglomerative hierarchical clustering using Int. J. Mol. Sci. 2011, 12                   
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the Pearson correlation as described in each figure. For pathway analysis, the average gene expression 
ratios were calculated as the in silico pool of treated animals versus the corresponding vehicle controls 
using the Rosetta Resolver error model. Genes with a fold change over 2 and a p-value < 0.01 were 
mapped to pathways and biological functions using Ingenuity Pathway Analysis (Ingenuity Systems, 
www.ingenuity.com).  
4. Conclusions 
In the present study, we have demonstrated that the QSI method can produce sufficient quantities of 
high quality RNA from small volumes (25–500 μL) of rat whole blood. Furthermore, the QSI method 
can generate microarray results comparable to the standard PAXgene method. Given the simplicity of 
this blood collection procedure and the minimal volume of blood required, the method can be easily 
applied for blood genomics profiling in pre-clinical species.  
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